| Branford S, Melo JV, Hughes TP
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure - does the BCR-ABL mutation status really matter? [JOURNAL ARTICLE]
Blood 2009 Oct 30.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| O'Hare T, Shakespeare WC, Zhu X, et al.
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance. [Journal Article]
Cancer Cell 2009 Nov 6; 16(5):401-12.
Abstract | Full Citation | Find Related Articles |
| Santos FP, Rodrigues M, Mac-Donald Bley do Nascimento C, et al.
Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib. [JOURNAL ARTICLE]
Cytotherapy 2009 Nov 2.
Abstract | Full Citation | Find Related Articles |
| Radujkovic A, Fruehauf S, Zeller WJ, et al.
Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells. [JOURNAL ARTICLE]
Cancer Chemother Pharmacol 2009 Oct 28.
Abstract | Full Citation |
| Guo T, Hajdu M, Agaram NP, et al.
Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance. [JOURNAL ARTICLE]
Clin Cancer Res 2009 Oct 27.
Abstract | Full Citation |
| Krauth MT, Mirkina I, Herrmann H, et al.
Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. [Journal Article]
Clin Exp Allergy 2009 Nov; 39(11):1711-20.
Abstract | Full Citation |
| Tojo A
[Clinical utility of tyrosine kinase inhibitors in myeloid leukemias] [English Abstract, Journal Article]
Nippon Rinsho 2009 Oct; 67(10):1926-31.
Abstract | Full Citation |
| Shen T, Kuang YH, Ashby CR, et al.
Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10). [Journal Article]
PLoS One 2009; 4(10):e7520.
Abstract | Full Citation |
| Milojkovic D, Nicholson E, Apperley JF, et al.
Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia. [JOURNAL ARTICLE]
Haematologica 2009 Oct 14.
Abstract | Full Citation |
| Rosti G, Palandri F, Castagnetti F, et al.
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. [JOURNAL ARTICLE]
Blood 2009 Oct 12.
Abstract | Full Citation | Find Related Articles |
   |
